Stocks · News reference
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on analyst ratings page. Follow other analysts.
Read original at benzingaWalmart, Amazon and PayPal feature among major retail and financial services developments spanning earnings, investments, drone delivery and potential acquisition talks.
Read original at benzingaBMO Capital analyst Harsh Kumar initiates coverage on Analog Devices (NASDAQ:ADI) with a Outperform rating and announces Price Target of $430.
Read original at benzingaSummit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.
Read original at zacks-investment-research